This Article Free Full Text (Free PDF) Free All Versions of this Article: 0269881105056668v1 20/1/104    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (13) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Weiden, P. J. Search for Related Content PubMed PubMed Citation Articles by Weiden, P. J. Social Bookmarking                         What's this?

Switching antipsychotics: an updated review with a focus on quetiapine

Department of Psychiatry, SUNY Downstate Medical Center, Brooklyn, NY, USA, peter.weiden{at}downstate.edu

Atypical antipsychotics offer broader efficacy and improved tolerability compared with conventional agents. Many patients currently treated with conventional antipsychotics continue to experience persistent symptoms or troublesome side effects and may benefit from a change to one of the newer atypical agents. There are also significant differences in the side-effect profiles of the atypicals, such that a switch from one atypical agent to another could offer advantages to many patients. Unfortunately, many clinicians remain uncertain about the switching process and are reluctant to initiate change. The aim of this review is to identify the indications for a switch in antipsychotic therapy with a focus on recent switching data for the atypical antipsychotic, quetiapine. The clinical aspects of quetiapine’s receptor binding characteristics are reviewed including the implications of the low D₂ antagonist properties that make quetiapine the treatment of choice when EPS persists with other atypical antipsychotics. Practical guidelines are given for managing the process of changeover, for avoiding pitfalls and for maximizing the chances of a successful switch. For example, when managing the antipsychotic crossover, it is important to consider the psychological effects of switching arising from symptom and side-effect changes. Finally, advice is provided on the assessments necessary when evaluating the success of a change in therapy, together with guidance on the optimal duration of treatment trials.

Key Words: schizophrenia • antipsychotics • partial response • quetiapine • anticholinergic • EPS • switching • withdrawal

This version was published on January 1, 2006

Journal of Psychopharmacology, Vol. 20, No. 1, 104-118 (2006)
DOI: 10.1177/0269881105056668


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Goudie and J. Cole Switching antipsychotics. Antipsychotic tolerance, withdrawal and relapse: unresolved issues and research implications J Psychopharmacol, September 1, 2008; 22(7): 815 - 817. [PDF]

				A. C. Singh, A. J. Massey, M. D. Thompson, L. R. Rappa, and M. S. Honeywell Addressing Nonadherence in the Schizophrenic Population Journal of Pharmacy Practice, December 1, 2006; 19(6): 361 - 368. [Abstract] [PDF]